Effectiveness of Scotland's National Naloxone Programme for reducing opioid-related deaths: a before (2006-10) versus after (2011-13) comparison

Sheila M. Bird, Andrew McAuley, Samantha Perry, Carole Hunter

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Aims: To assess the effectiveness for Scotland's National Naloxone Programme (NNP) bycomparison between 2006-10 (before) and 2011-13 (after NNP started in January2011) and to assess cost-effectiveness.
Design: This was a pre-post evaluation of a national policy. Cost-effectiveness was assessedby prescription costs against life-years gained per opioid-related death (ORD) averted.
Setting: Scotland, in community settings and all prisons.
Intervention: Brief training and standardized naloxone supply became available to individuals at risk of opioid overdose.
Measurements: ORDs as identified by National Records of Scotland. Look-back determined the proportion of ORDs who, in the 4 weeks before ORD, had been (i) released from prison (primary outcome) and (ii) released from prison or discharged from hospital (secondary). We report 95% confidence intervals for effectiveness inreducing the primary (and secondary) outcome in 2011-13 versus 2006-10. Prescription costs were assessed against 1 or 10 life-years gained per averted ORD.
Findings: In 2006-10, 9.8% of ORDs (193 of 1970) were in people released from prison within 4 weeks of death, whereas only 6.3% of ORDs in 2011-13 followed prison release(76 of 1212, P < 0.001; this represented a difference of 3.5% [95% confidence interval (CI) = 1.6-5.4%)]. This reduction in the proportion of prison release ORDs translates into 42 fewer prison release ORDs (95% CI =19-65) during 2011-13, when 12 000 naloxone kits were issued at current prescription cost of £225 000. Scotland's secondary outcome reduced from 19.0 to 14.9%, a difference of 4.1% (95% CI = 1.4-6.7%).
Conclusions: Scotland's National Naloxone Programme, which started in 2011, was associated with a 36% reduction in the proportion of opioid-related deaths that occurred in the 4 weeks following release from prison.
LanguageEnglish
Number of pages9
JournalAddiction
Early online date4 Feb 2016
DOIs
Publication statusE-pub ahead of print - 4 Feb 2016

Fingerprint

Prisons
Scotland
Naloxone
Opioid Analgesics
Confidence Intervals
Prescriptions
Costs and Cost Analysis
Cost-Benefit Analysis

Keywords

  • before/after policy evaluation
  • causality
  • effectiveness
  • national naloxone programme
  • opioid-related deaths
  • prison release opioid-related deaths
  • statistical power
  • take-home naloxone

Cite this

@article{db59208a5cde4d6aab455edcbf357c88,
title = "Effectiveness of Scotland's National Naloxone Programme for reducing opioid-related deaths: a before (2006-10) versus after (2011-13) comparison",
abstract = "Aims: To assess the effectiveness for Scotland's National Naloxone Programme (NNP) bycomparison between 2006-10 (before) and 2011-13 (after NNP started in January2011) and to assess cost-effectiveness.Design: This was a pre-post evaluation of a national policy. Cost-effectiveness was assessedby prescription costs against life-years gained per opioid-related death (ORD) averted.Setting: Scotland, in community settings and all prisons.Intervention: Brief training and standardized naloxone supply became available to individuals at risk of opioid overdose.Measurements: ORDs as identified by National Records of Scotland. Look-back determined the proportion of ORDs who, in the 4 weeks before ORD, had been (i) released from prison (primary outcome) and (ii) released from prison or discharged from hospital (secondary). We report 95{\%} confidence intervals for effectiveness inreducing the primary (and secondary) outcome in 2011-13 versus 2006-10. Prescription costs were assessed against 1 or 10 life-years gained per averted ORD.Findings: In 2006-10, 9.8{\%} of ORDs (193 of 1970) were in people released from prison within 4 weeks of death, whereas only 6.3{\%} of ORDs in 2011-13 followed prison release(76 of 1212, P < 0.001; this represented a difference of 3.5{\%} [95{\%} confidence interval (CI) = 1.6-5.4{\%})]. This reduction in the proportion of prison release ORDs translates into 42 fewer prison release ORDs (95{\%} CI =19-65) during 2011-13, when 12 000 naloxone kits were issued at current prescription cost of £225 000. Scotland's secondary outcome reduced from 19.0 to 14.9{\%}, a difference of 4.1{\%} (95{\%} CI = 1.4-6.7{\%}).Conclusions: Scotland's National Naloxone Programme, which started in 2011, was associated with a 36{\%} reduction in the proportion of opioid-related deaths that occurred in the 4 weeks following release from prison.",
keywords = "before/after policy evaluation, causality, effectiveness, national naloxone programme, opioid-related deaths, prison release opioid-related deaths, statistical power, take-home naloxone",
author = "Bird, {Sheila M.} and Andrew McAuley and Samantha Perry and Carole Hunter",
year = "2016",
month = "2",
day = "4",
doi = "10.1111/add.13265",
language = "English",
journal = "Addiction",
issn = "0965-2140",

}

Effectiveness of Scotland's National Naloxone Programme for reducing opioid-related deaths : a before (2006-10) versus after (2011-13) comparison. / Bird, Sheila M.; McAuley, Andrew; Perry, Samantha; Hunter, Carole.

In: Addiction, 04.02.2016.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effectiveness of Scotland's National Naloxone Programme for reducing opioid-related deaths

T2 - Addiction

AU - Bird, Sheila M.

AU - McAuley, Andrew

AU - Perry, Samantha

AU - Hunter, Carole

PY - 2016/2/4

Y1 - 2016/2/4

N2 - Aims: To assess the effectiveness for Scotland's National Naloxone Programme (NNP) bycomparison between 2006-10 (before) and 2011-13 (after NNP started in January2011) and to assess cost-effectiveness.Design: This was a pre-post evaluation of a national policy. Cost-effectiveness was assessedby prescription costs against life-years gained per opioid-related death (ORD) averted.Setting: Scotland, in community settings and all prisons.Intervention: Brief training and standardized naloxone supply became available to individuals at risk of opioid overdose.Measurements: ORDs as identified by National Records of Scotland. Look-back determined the proportion of ORDs who, in the 4 weeks before ORD, had been (i) released from prison (primary outcome) and (ii) released from prison or discharged from hospital (secondary). We report 95% confidence intervals for effectiveness inreducing the primary (and secondary) outcome in 2011-13 versus 2006-10. Prescription costs were assessed against 1 or 10 life-years gained per averted ORD.Findings: In 2006-10, 9.8% of ORDs (193 of 1970) were in people released from prison within 4 weeks of death, whereas only 6.3% of ORDs in 2011-13 followed prison release(76 of 1212, P < 0.001; this represented a difference of 3.5% [95% confidence interval (CI) = 1.6-5.4%)]. This reduction in the proportion of prison release ORDs translates into 42 fewer prison release ORDs (95% CI =19-65) during 2011-13, when 12 000 naloxone kits were issued at current prescription cost of £225 000. Scotland's secondary outcome reduced from 19.0 to 14.9%, a difference of 4.1% (95% CI = 1.4-6.7%).Conclusions: Scotland's National Naloxone Programme, which started in 2011, was associated with a 36% reduction in the proportion of opioid-related deaths that occurred in the 4 weeks following release from prison.

AB - Aims: To assess the effectiveness for Scotland's National Naloxone Programme (NNP) bycomparison between 2006-10 (before) and 2011-13 (after NNP started in January2011) and to assess cost-effectiveness.Design: This was a pre-post evaluation of a national policy. Cost-effectiveness was assessedby prescription costs against life-years gained per opioid-related death (ORD) averted.Setting: Scotland, in community settings and all prisons.Intervention: Brief training and standardized naloxone supply became available to individuals at risk of opioid overdose.Measurements: ORDs as identified by National Records of Scotland. Look-back determined the proportion of ORDs who, in the 4 weeks before ORD, had been (i) released from prison (primary outcome) and (ii) released from prison or discharged from hospital (secondary). We report 95% confidence intervals for effectiveness inreducing the primary (and secondary) outcome in 2011-13 versus 2006-10. Prescription costs were assessed against 1 or 10 life-years gained per averted ORD.Findings: In 2006-10, 9.8% of ORDs (193 of 1970) were in people released from prison within 4 weeks of death, whereas only 6.3% of ORDs in 2011-13 followed prison release(76 of 1212, P < 0.001; this represented a difference of 3.5% [95% confidence interval (CI) = 1.6-5.4%)]. This reduction in the proportion of prison release ORDs translates into 42 fewer prison release ORDs (95% CI =19-65) during 2011-13, when 12 000 naloxone kits were issued at current prescription cost of £225 000. Scotland's secondary outcome reduced from 19.0 to 14.9%, a difference of 4.1% (95% CI = 1.4-6.7%).Conclusions: Scotland's National Naloxone Programme, which started in 2011, was associated with a 36% reduction in the proportion of opioid-related deaths that occurred in the 4 weeks following release from prison.

KW - before/after policy evaluation

KW - causality

KW - effectiveness

KW - national naloxone programme

KW - opioid-related deaths

KW - prison release opioid-related deaths

KW - statistical power

KW - take-home naloxone

UR - http://www.scopus.com/inward/record.url?scp=84959450150&partnerID=8YFLogxK

UR - http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1360-0443

U2 - 10.1111/add.13265

DO - 10.1111/add.13265

M3 - Article

JO - Addiction

JF - Addiction

SN - 0965-2140

ER -